Drugs Controller General of India (DCGI), has granted a conditional market authorisation for Covishield and Covaxin, under the New Drugs and Clinical Trials Rules, 2019.
This approval is an upgrade from the emergency use authorisation and largely represents a regulatory endorsement of the safety doses. However, this doesn’t mean the two COVID-19 vaccines will be available at shops soon though people would be able to buy them from hospitals and clinics.
India has reported 2,51,209 new COVID-19 cases and 627 deaths as on 28 January 2022. This is the fourth consecutive day that the country has reported below three lakh cases. Total number of infections in the country now stands at 4 crore 6 lakh cases and the total number of Covid-related fatalities are 4,92,327. The new cases reported are 12% lower than yesterday’s daily spike of 2.86 lakh cases.
There are presently 21 lakh active cases in India. The active cases comprise 5.18 per cent of the total infections, while the national COVID-19 recovery rate is 93.6 per cent. The daily positivity rate is down from 19.59% to 15.88% while the weekly positivity rate was recorded at 17.47 per cent.
India’s COVID-19 vaccination coverage has crossed 164.4 crore doses, out of which 89.1 crore first doses have been administered and 69.9 crore second doses have been provided. At least 72 per cent of India’s adult population is fully vaccinated and around 52 per cent of children in the 15-18 years old age group have been inoculated with the first dose of Covid vaccine.